AI Prospecting for Bristol-Myers Squibb
Company data:
Company size:
34100 employeesWebsite URL:
https://www.bms.comIndustry
PharmaceuticalsHeadquarters:
430 E. 29th Street, New York, NY 10016, USAInvestment round:
Publicly Traded (NYSE: BMY)ARR:
$46 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Bristol-Myers Squibb
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Bristol Myers Squibb announced that the Phase 3 ODYSSEY-HCM trial for Camzyos (mavacamten) in non-obstructive hypertrophic cardiomyopathy did not meet its primary endpoints, though no new safety signals were observed. Additionally, the FDA approved Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR colorectal cancer, and updated the CAMZYOS label to reduce echocardiography monitoring requirements[2][4][5].
Bristol Myers Squibb will announce its first quarter 2025 financial results on April 24, 2025, with a conference call starting at 8:00 a.m. ET, and materials will be available at http://investor.bms.com[4].
Bristol Myers Squibb has entered an agreement with Optellum to leverage AI for early diagnosis and precision lung cancer care. Optellum's AI-powered imaging and clinical decision support platform will be deployed to evaluate its real-world impact on patient outcomes, aiming to identify pre-symptomatic cancers through automated analysis of CT scans[5].
Open job positions at Bristol-Myers Squibb
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Executive Director, Cell Therapy Analytical Development
IO Senior Area Sales Manager
IO Account Executive
